RATIONALE AND OBJECTIVES: Echogenic immunoliposomes (ELIP) for enhancement of vasoactive and pathologic components of endothelium and atherosclerosis have been developed. A physiologic flow chamber model has been developed to define intravascular ultrasound enhancement of a fibrin interface. METHODS: A IgG ELIP was used, which nonspecifically associated with fibrin, to demonstrate the suitability of this model. With varying doses of IgG ELIP, the fibrin wells were imaged at 1, 2, 4, 6, and 9 minutes. RESULTS: IgG ELIP enhanced fibrin versus saline (P < 0.005) was visible at 1 minute, lasted at least 9 minutes, and at 6 minutes the interface enhanced 27% +/- 6.1%. Enhancement was caused by increases in interface thickness and brightness. Enhancement increased with dose up to 8 mg lipid (n = 4 per time point). CONCLUSION: This model can quantitate the components of IVUS enhancement of an interface produced by ELIP. This model may allow for further development and understanding of ELIP and other targeted ultrasound contrast agents.
RATIONALE AND OBJECTIVES: Echogenic immunoliposomes (ELIP) for enhancement of vasoactive and pathologic components of endothelium and atherosclerosis have been developed. A physiologic flow chamber model has been developed to define intravascular ultrasound enhancement of a fibrin interface. METHODS: A IgG ELIP was used, which nonspecifically associated with fibrin, to demonstrate the suitability of this model. With varying doses of IgG ELIP, the fibrin wells were imaged at 1, 2, 4, 6, and 9 minutes. RESULTS: IgG ELIP enhanced fibrin versus saline (P < 0.005) was visible at 1 minute, lasted at least 9 minutes, and at 6 minutes the interface enhanced 27% +/- 6.1%. Enhancement was caused by increases in interface thickness and brightness. Enhancement increased with dose up to 8 mg lipid (n = 4 per time point). CONCLUSION: This model can quantitate the components of IVUS enhancement of an interface produced by ELIP. This model may allow for further development and understanding of ELIP and other targeted ultrasound contrast agents.
Authors: Constantin-C Coussios; Christy K Holland; Ludwika Jakubowska; Shao-Ling Huang; Robert C MacDonald; Ashwin Nagaraj; David D McPherson Journal: Ultrasound Med Biol Date: 2004-02 Impact factor: 2.998
Authors: Shao-Ling Huang; Patrick H Kee; Hyunggun Kim; Melanie R Moody; Stephen M Chrzanowski; Robert C Macdonald; David D McPherson Journal: J Am Coll Cardiol Date: 2009-08-11 Impact factor: 24.094
Authors: Patrick H Kee; Hyunggun Kim; Shaoling Huang; Susan T Laing; Melanie R Moody; Deborah Vela; Melvin E Klegerman; David D McPherson Journal: Ultrasound Med Biol Date: 2014-03-05 Impact factor: 2.998
Authors: Melvin E Klegerman; Michael Wassler; Shao-Ling Huang; Yuejiao Zou; Hyunggun Kim; Harnath S Shelat; Christy K Holland; Yong-Jian Geng; David D McPherson Journal: J Control Release Date: 2009-11-10 Impact factor: 9.776
Authors: Tao Peng; George L Britton; Hyunggun Kim; Davide Cattano; Jaroslaw Aronowski; James Grotta; David D McPherson; Shao-Ling Huang Journal: CNS Neurosci Ther Date: 2013-08-24 Impact factor: 5.243